Teva exec: Bills would burden drugmakers, delay generics

09/23/2009 | Nasdaq.com

Bill Marth, CEO of North American operations for Teva Pharmaceutical Industries, says health care reform bills proposed in the Senate and House unfairly burden drugmakers and would delay how quickly generics reach the market. The bills would prohibit makers of brand-name and generic drugs from negotiating pay-for-delay deals and require makers of generics to pay increased rebates to the government. "I think it is a problem to be taxing the very people who are giving the savings," Marth says.

View Full Article in:

Nasdaq.com